On April 28, 2026, China’s National Medical Products Administration (NMPA) released the Supplementary Guidance for Registration Review of Robotic Arm Liquid Devices, mandating PLd-level functional safety per ISO/IEC 13849-1 for human–robot collaborative systems in Class III liquid-handling robotic medical devices. This update directly affects manufacturers, importers, and clinical lab automation solution providers operating in or supplying to China’s regulated medical device market.

Event Overview

The National Medical Products Administration (NMPA) issued the Supplementary Guidance for Registration Review of Robotic Arm Liquid Devices on April 28, 2026. The guidance applies immediately and specifies that all Class III medical device registration applications for liquid-handling robotic arms must demonstrate compliance with Performance Level d (PLd) under ISO/IEC 13849-1 for human–machine collaborative safety functions. Applicants are required to submit a third-party functional safety validation report as part of the registration dossier.

Industries Affected by This Guidance

Medical device manufacturers (Class III liquid-handling robotic systems)
These companies are directly subject to the new requirement. Their product safety architecture—including safety-related control systems, emergency stop logic, speed/force limiting, and proximity sensing—must now be designed, verified, and documented to meet PLd. Impact manifests in extended development timelines, revised risk management files (per ISO 14971), and additional third-party assessment costs.

Third-party functional safety certification bodies
Organizations accredited to perform ISO/IEC 13849-1 assessments will see increased demand for PLd-level validation services targeting robotic arm liquid handlers. Workscope now explicitly includes verification of safety-related parts of control systems (SRP/CS) used in human–robot shared workspaces—especially where liquid handling introduces slip, spill, or electrical hazard considerations.

Importers and distributors of foreign-manufactured robotic liquid handlers
Entities bringing Class III robotic liquid-handling devices into China must ensure their overseas suppliers have completed PLd-compliant design and third-party validation prior to registration submission. Failure to provide the required report will result in registration rejection or significant delays during technical review.

Clinical laboratory automation integrators
While not direct registrants, integrators embedding robotic arm modules into larger lab automation platforms must confirm that each module’s safety subsystem meets PLd—particularly when human operators interact with the robot during loading/unloading, maintenance, or error recovery. System-level safety validation may now require re-evaluation if legacy modules were certified only to lower PLs (e.g., PLc).

What Relevant Enterprises or Practitioners Should Focus On — And How to Respond Now

Monitor official NMPA implementation clarifications

NMPA has not yet published accompanying FAQs or technical Q&As. Stakeholders should track updates from the Center for Medical Device Evaluation (CMDE) and attend upcoming NMPA-hosted webinars or consultation sessions—especially those addressing scope boundaries (e.g., whether ‘liquid handling’ covers reagent dispensing only, or also includes sample aspiration, mixing, or waste aspiration).

Review current product safety documentation against PLd requirements

Manufacturers should conduct an immediate gap assessment: compare existing safety architecture (including hardware fault tolerance, diagnostic coverage, and common cause failure mitigation) against PLd criteria in ISO/IEC 13849-1 Annexes K and L. Particular attention is needed for Category 3 architecture with DC > 90% and MTTF_D ≥ 10 years—common thresholds for PLd achievement.

Distinguish between regulatory signal and operational readiness

This guidance signals NMPA’s prioritization of human–robot interaction safety in high-risk automation—not a broad expansion to all robotics. It does not apply to non-liquid-handling robots (e.g., surgical manipulators or transport robots) nor to Class I/II devices. Companies should avoid overgeneralizing the requirement across product lines without verifying scope alignment.

Initiate third-party engagement early for validation planning

Lead times for PLd-level functional safety validation can exceed 12 weeks due to test complexity and backlog at accredited labs. Firms preparing submissions should engage certified bodies now—not after finalizing design—to align on test plans, evidence formats, and documentation expectations per CMDE’s current review practices.

Editorial Perspective / Industry Observation

Observably, this guidance reflects NMPA’s increasing emphasis on harmonizing domestic regulatory expectations with internationally accepted functional safety benchmarks—particularly for automation technologies entering clinical environments where operator proximity is routine. Analysis shows it functions less as a standalone policy shift and more as a targeted calibration: reinforcing existing ISO 13849-1 adoption while closing a previously unaddressed gap in collaborative liquid-handling robotics. From an industry perspective, it signals growing regulatory scrutiny of real-time safety performance—not just static mechanical compliance—and suggests future guidance may extend similar PL requirements to other collaborative modalities (e.g., vision-guided or force-sensing interactions). Continuous monitoring remains essential, as no transitional period or grandfathering clause has been announced.

Conclusion
This guidance establishes a clear, enforceable safety benchmark for a specific but high-growth segment of medical robotics in China. Its significance lies not in novelty—PLd is well-established globally—but in its formal codification within NMPA’s registration framework for the first time in this application domain. It is best understood not as an isolated rule change, but as a concrete indicator of NMPA’s maturing risk-based approach to AI- and robotics-enabled medical devices.

Information Sources
Primary source: National Medical Products Administration (NMPA), Supplementary Guidance for Registration Review of Robotic Arm Liquid Devices, effective April 28, 2026.
Note: Ongoing observation is warranted for CMDE-issued implementation notes, scope clarifications, or updates to the Technical Review Guidelines for Medical Robotics that may reference or contextualize this supplement.